Shares of Legal & General Group Plc (LON:LGEN – Get Rating) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 250.53 ($3.10) and traded as high as GBX 259 ($3.21). Legal & General Group shares last traded at GBX 256.80 ($3.18), with a volume of 15,631,298 shares traded.
Analysts Set New Price Targets
A number of brokerages recently issued reports on LGEN. Barclays reiterated an “overweight” rating and issued a GBX 397 ($4.92) price objective on shares of Legal & General Group in a research report on Wednesday, November 30th. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 375 ($4.64) price target on shares of Legal & General Group in a research report on Wednesday, October 5th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Legal & General Group from GBX 285 ($3.53) to GBX 290 ($3.59) and gave the stock a “buy” rating in a report on Monday, November 21st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 341 ($4.22).
Legal & General Group Stock Performance
The company has a 50-day simple moving average of GBX 254.88 and a two-hundred day simple moving average of GBX 250.65. The company has a debt-to-equity ratio of 452.13, a quick ratio of 0.50 and a current ratio of 0.90. The firm has a market capitalization of £15.48 billion and a P/E ratio of 760.46.
Insider Buying and Selling at Legal & General Group
Legal & General Group Company Profile
Legal & General Group Plc provides various insurance products and services in the United Kingdom, the United States, and internationally. It operates in four segments: Legal & General Retirement (LGR), Legal & General Investment Management (LGIM), Legal & General Capital (LGC), and Legal & General Insurance (LGI).
Featured Stories
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Legal & General Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legal & General Group and related companies with MarketBeat.com's FREE daily email newsletter.